NCT03326128

High Dose Bupropion for Smoking Cessation - Pilot Study

High Dose Bupropion Treatment for Smoking Cessation - Pilot Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study aims to investigate the benefit of administering two differing doses of Bupropion (BUP) to smokers to assist with smoking cessation.

Detailed description

Participants will be randomly assigned to either receive 300 mg of BUP or 450 mg of BUP for 8 weeks with an aim to quit smoking. In addition, participants will simultaneously receive counseling to set a quit date and stay motivated to quit. Medication will be administered up to 4 weeks before and for 4 weeks after designated quit-date. Post-treatment follow-up appointment will be scheduled for 8, 16, and 26 weeks post treatment to assess commitment to quitting and overall success of the study.

Conditions

• Smoking Cessation
• Smoking, Tobacco
• Smoking (Tobacco) Addiction
• Cessation, Tobacco
• Cigarette Smoking

Interventions

Type	Name	Description
DRUG	Bupropion Hydrochloride	Antidepressant that is also effective in smoking cessation

Timeline

• Start date: 2021-09-01
• Primary completion: 2023-07-01
• Completion: 2023-07-01
• First posted: 2017-10-31
• Last updated: 2023-07-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study